OUR MOTIVATION

only

10%

of cancer patients benefit from approved therapies

95%

of anti-cancer drugs fail to be approved for patients due to lack of efficacy

1B USD

IS THE COST TO DEVELOP EACH ANTI-CANCER DRUG

We are Marie-Agnès Doucey and Riccardo Turrini, co-founders of Calico Biosystems.

We have been educated as scientists, like many of you. Over the years, we have witnessed the critical issue of the limited efficacy of anti-cancer drugs in patients with solid tumors, the huge attrition rate of drugs from the pre-clinical stage to approval for use in patients, and their high development costs.

We want to change the status quo and provide cancer patients with new effective drugs, more potent combinations of therapies, and a real chance to get cured. Together, we have founded Calico Biosystems.

Partner with us to join the revolution of Precision Oncology.

MEET OUR TEAM AND BOARDS

Our Team

Marie-Agnès Doucey, PhD & engineer CEO and co-founder

15+ yrs as head of RnD and drug development programs in Oncology in public and private sectors, VP in Oncology

Riccardo Turrini, PhD in Oncology/Immunology CSO and
co-founder 

15+ yrs experience in deciphering the immune response in tumors, program and team leader

Olivier Lacoste, MBA CFO

30+ yrs international experience 20 yrs M&A and Business Dev. 10+ yrs in Pharma Pharma and CRO network 

Our Scientific Board

Our Scientific Board

Our Advisory Board

Michael Pittet, Director

Translation Oncology, HUG Translational oncology expert

Michael Pittet, Director

Translation Oncology, HUG Translational oncology expert

Michail Ignatiadis, Director

Clinical Oncology, Jules Bordet Institute, Brussels; chair at the EORTC Clinical oncology expert

Michail Ignatiadis, Director

Clinical Oncology, Jules Bordet Institute, Brussels; chair at the EORTC Clinical oncology expert

Our Advisory Board

Jean Pierre Wery

Former CTO of Crown Bioscience/ JSR LifeSciences, CEO SideWinder Therapeutics Network and contact with VCs and customers

Jean Pierre Wery

Former CTO of Crown Bioscience/ JSR LifeSciences, CEO SideWinder Therapeutics Network and contact with VCs and customers

Ioannis Xenarios

Professor, Unil, Head of Systems Computational Bioinformatics, Health2030 Genome Center. Our bioinformatic expert & counselor

Ioannis Xenarios

Professor, Unil, Head of Systems Computational Bioinformatics, Health2030 Genome Center. Our bioinformatic expert & counselor

contact us

We’d love to hear from you!

15 + 6 =